Pipeline
PROGRAM
DISEASE
DISCOVERY
PRE-CLINICAL
PHASE 1/2
PIVOTAL
AML
WU-NK-101
Head & Neck Cancer
WU-NK-101 + Cetuximab
WU-NK
Melanoma
WU-NK-101 (post-checkpoint inhibitor)
Undisclosed
WU-NK-201
T-ALL/T-NHL
WU-CART-007
WU-CART
T-NHL
WU-CART-002
AML = Acute Myeloid Leukemia
T-ALL = T-cell Acute Lymphoblastic Leukemia
T-NHL = T-cell Non-Hodgkin’s Lymphoma
